Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy

BACKGROUND: A human chorionic gonadotropin (hCG) cut-off of ≤300 IU/l for starting actinomycin D (ActD) in post-molar gestational trophoblastic neoplasia (GTN) patients developing methotrexate resistance (MTX-R) reduced the number of women needing toxic multi-agent chemotherapy (etoposide, MTX and A...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortés-Charry, R., Hennah, L., Froeling, F.E.M., Short, D., Aguiar, X., Tin, T., Harvey, R., Unsworth, N., Kaur, B., Savage, P., Sarwar, N., Seckl, M.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044379/
https://www.ncbi.nlm.nih.gov/pubmed/33845362
http://dx.doi.org/10.1016/j.esmoop.2021.100110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044379/
https://www.ncbi.nlm.nih.gov/pubmed/33845362
http://dx.doi.org/10.1016/j.esmoop.2021.100110

Ejemplares similares